COVID-19 Resource Center

COVID-19 Resource Center

Source:

Press Release

Disclosures: Healio Primary Care was unable to determine relevant financial disclosures at the time of publication.
May 11, 2022
1 min read
Save

FDA approves Olumiant for certain adults hospitalized with COVID-19

Source:

Press Release

Disclosures: Healio Primary Care was unable to determine relevant financial disclosures at the time of publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has approved a new indication for Olumiant as a treatment for adults hospitalized with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

The Janus kinase inhibitor Olumiant (baricitinib; Eli Lilly & Co.) is the first immunomodulatory treatment to be approved by the FDA for COVID-19, according to the agency.

FDA approval
Source: Adobe Stock

The FDA previously granted emergency use authorization (EUA) to baricitinib for use in combination with Veklury (remdesivir; Gilead Sciences) as a treatment for adults and pediatric patients hospitalized with COVID-19. The EUA was later updated to authorize baricitinib as a standalone treatment, the FDA said. The drug remains under EUA status for hospitalized patients aged 2 to 17 years who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

The new indication of baricitinib is supported by findings from two randomized, double-blind, placebo-controlled phase 3 studies, ACTT-2 and COV-BARRIER, which demonstrated mortality benefits with baricitinib in patients hospitalized with COVID-19, according to the manufacturer.

“More than 2 years into the pandemic, COVID-19 is still hospitalizing many people and burdening our health care system. I’m grateful to have Olumiant as a treatment option for those who require various degrees of respiratory support, from supplemental oxygen to mechanical ventilation or ECMO,” Andre Kalil, MD, MPH, a professor of medicine at the University of Nebraska Medical Center and principal investigator of the ACTT-2 trial, said in a press release from Eli Lilly & Co. “While there are therapies currently available, there is still an urgent need for more options to help improve outcomes for patients hospitalized due to COVID-19.”

The FDA-approved labeling for baricitinib includes a boxed warning about an increased risk for serious infections, including tuberculosis, as well as mortality, malignancy, major adverse cardiovascular events and thrombosis, the manufacturer said.

Reference:

Olumiant prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf?utm_medium=email&utm_source=govdelivery. Accessed May 11, 2022.